Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ameriprise Financial

Blackrock Inc

Cummins

CNH Industrial NV

Canadian Natural Resources

ConocoPhillips

General Mills

Genuine Parts

Hartford Financial Services Group

Hubbell

Infosys

KLA-Tencor

Kroger

Merck

NetEase

Novo Nordisk

Novartis

Taiwan Semiconductor Manufacturing

United Microelectronics

The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-year returns.

V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023

INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on June 9, 2023 to shareholders of record at the close of business on May 15, 2023.

Lilly Declares Second-Quarter 2023 Dividend

INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab's stable and long-lasting results at one year of treatment in patients with moderate-to-severe atopic dermatitis (AD), commonly called eczema.

Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Biogen

Quest Diagnostics

Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.

Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease

The pharmaceutical company benefitted from a clutch of analyst price-target raises. These followed Lilly's well-received earnings report.

Why Eli Lilly Stock Was a Winner Today

This trade is a neutral to bullish position and anticipates the stock holding above 390 over the summer term. The post Lilly Has Plans For Possible Anti-Obesity Medication.

Lilly Has Plans For Possible Anti-Obesity Medication. Here's How To Make Money With LLY Options

Apple

Costco

Kraft Heinz

Procter & Gamble

The Federal Reserve is now forecasting a mild recession for later this year. When uncertainty picks up, investors typically flock to safe stocks.

5 Brand-Name Safe Stocks I Wouldn't Touch With a 10-Foot Pole Right Now

Lilly is now racing toward likely approval for Mounjaro in treating obesity after positive late-stage results. The bigger picture for the company also looks good overall.

Is Eli Lilly Stock a No-Brainer Buy After Mounjaro's Latest Big Win?

Eli Lilly and Company (LLY) Q1 2023 Earnings Call Transcript.

Eli Lilly and Company (LLY) Q1 2023 Earnings Call Transcript

Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.

Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised

Eli Lilly & Co stock climbed after the drug maker reported first-quarter earnings showing a revenue beat and raised its full-year guidance. For the quarter ended March 31, 2023, the Indianapolis-based pharma giant reported that revenue declined 11% to $6.96 billion from $7.81 billion, but was well ahead of the $6.864 billion FactSet estimate.

Eli Lilly stock rises after 1Q revenue beat and pipeline momentum from diabetes and weight loss drug Tirzepatide

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Lilly (LLY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Mounjaro excitement more than makes up for company's first quarter results.

Obesity Drug Hype Outweighs Profit Miss at Eli Lilly

Eli Lilly (NYSE: LLY ) stock is climbing higher on Thursday thanks to a boost from Mounjaro during its earnings report for the first quarter of 2023. According to the company, diabetes drug Mounjaro strongly contributed to its revenue during the quarter.

LLY Stock Alert: Mounjaro Takes Eli Lilly to the Next Level

Late-stage trials suggest Lilly's tirzepatide, sold under Mounjaro, could be a more effective obesity drug that Ozempic or Wegovy, and the company expects a regulatory decision by the end of the year.

Eli Lilly Pushes For Fast-Track Approval Of Mounjaro As Weight-Loss Drug

Shares have been on the volatile side this year due to a slew of headwinds. Over the long term, these headwinds will likely fade due to the growth potential of its rapidly emerging flagship drug, Mounjaro.

Is Eli Lilly Stock a Strong Buy After Q1 Earnings?

Eli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.

Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds

Eli Lilly (LLY) came out with quarterly earnings of $1.62 per share, missing the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.62 per share a year ago.

Eli Lilly (LLY) Q1 Earnings Lag Estimates

Eli Lilly stock jumped Thursday on better-than-expected sales of diabetes newcomer, Mounjaro, helping offset a massive Covid-related decline. The post Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water appeared first on Investor's Business Daily.

Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water

The company reported adjusted earnings of $1.62, which missed analyst expectations of $1.73 for the quarter.

Eli Lilly misses on earnings but raises full-year guidance

Eli Lilly & Co. shares LLY rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance. The company posted net income of $1.345 billion, or $1.49 a share, for the quarter, down from $1.903 billion, or $2.10 a share, in the year-earlier period.

Eli Lilly stock up premarket as company's Q1 revenue beats and it raises guidance

Abbott Labs

Intuitive Surgical

McKesson

Danaher

Moderna

UnitedHealth Group

Healthcare stocks are one of the best bets out there. The U.S. spends more on healthcare than any other country.

7 Healthcare Stocks With Huge Return Potential for Long-Term Investors

Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth from Mounjaro, Trulicity, Verzenio and Jardiance.

Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum

Eli Lilly & Co. LLY said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage trial. Participants in the phase 3 trial called Surmount-2 lost up to 34.4 pounds, the company said in a statement.

Eli Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trial

Participants with obesity or overweight and type 2 diabetes taking tirzepatide lost up to 34.4 lb. (15.6 kg) Lilly plans to complete rolling submission to the FDA in the coming weeks INDIANAPOLIS , April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.

News for Eli Lilly Stock (LLY)